PL3236967T3 - Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego - Google Patents

Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego

Info

Publication number
PL3236967T3
PL3236967T3 PL15817516T PL15817516T PL3236967T3 PL 3236967 T3 PL3236967 T3 PL 3236967T3 PL 15817516 T PL15817516 T PL 15817516T PL 15817516 T PL15817516 T PL 15817516T PL 3236967 T3 PL3236967 T3 PL 3236967T3
Authority
PL
Poland
Prior art keywords
prevention
treatment
cancer patients
metastatic disease
thrombocytotic
Prior art date
Application number
PL15817516T
Other languages
English (en)
Inventor
Stephen Damment
Richard Franklin
Jorge Daniel Erusalimsky
Original Assignee
Suda Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suda Pharmaceuticals Ltd filed Critical Suda Pharmaceuticals Ltd
Publication of PL3236967T3 publication Critical patent/PL3236967T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL15817516T 2014-12-22 2015-12-22 Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego PL3236967T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422978 2014-12-22
PCT/GB2015/054116 WO2016102952A1 (en) 2014-12-22 2015-12-22 Prevention and treatment of metastatic disease in thrombocytotic cancer patients
EP15817516.6A EP3236967B1 (en) 2014-12-22 2015-12-22 Prevention and treatment of metastatic disease in thrombocytotic cancer patients

Publications (1)

Publication Number Publication Date
PL3236967T3 true PL3236967T3 (pl) 2020-04-30

Family

ID=55066666

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15817516T PL3236967T3 (pl) 2014-12-22 2015-12-22 Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego

Country Status (10)

Country Link
US (1) US11324746B2 (pl)
EP (2) EP3659605A1 (pl)
JP (2) JP6716570B2 (pl)
CN (2) CN107206000A (pl)
AU (1) AU2015370666B2 (pl)
DK (1) DK3236967T3 (pl)
ES (1) ES2761776T3 (pl)
PL (1) PL3236967T3 (pl)
PT (1) PT3236967T (pl)
WO (1) WO2016102952A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2681300C1 (ru) * 2017-10-27 2019-03-05 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России Способ лечения диссеминированного почечно-клеточного рака
GB202103100D0 (en) 2021-03-05 2021-04-21 Suda Pharmaceuticals Ltd Mitigating the off-target pharmacology of anagrelide in the treatment of thrombocytosis in various diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166312C (en) 1993-06-29 2002-04-23 Alan Harris Compositions for nasal administration of desmopressin
ATE219934T1 (de) 1995-04-14 2002-07-15 Smithkline Beecham Corp Dosierinhalator für albuterol
BR0111747A (pt) 2000-06-28 2003-07-08 Smithkline Beecham Plc Processo de moagem úmida
DK1542657T3 (da) 2002-08-14 2012-03-05 Gw Pharma Ltd Flydende cannabinoidformuleringer til administration via en slimhinde
PL377933A1 (pl) 2003-01-23 2006-02-20 Shire Holdings Ag Formulacja i sposoby leczenia trombocytemii
US20070104763A1 (en) 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
GB0623749D0 (en) 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
US20100111901A1 (en) * 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
WO2011036521A2 (en) 2009-09-25 2011-03-31 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
RS53960B1 (en) * 2010-03-25 2015-08-31 Aop Orphan Pharmaceuticals Ag NEW COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTEMIA
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
US9574001B2 (en) * 2012-08-02 2017-02-21 New York University Humanized single-chain antibody against beta 3 integrin for the treatment and prevention of metastasis
US9890127B2 (en) 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
EP2969148B1 (en) 2013-03-12 2018-02-21 Aperia Technologies, Inc. Pump with water management
CN104161759B (zh) 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
JP6445573B2 (ja) 2013-10-17 2018-12-26 サルタル セラピューティクス エルティーディSartar Therapeutics Ltd ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
BR122021026776B1 (pt) 2014-02-28 2023-03-28 Altria Client Services Llc Componente de reservatório de líquido de um dispositivo de vaporação eletrônico
EP3210604B1 (en) 2014-10-24 2024-02-14 Launxp Biomedical Co., Ltd. Uses of duloxetine hcl medicament in preparing pharmaceutical composition for treatment of cancer

Also Published As

Publication number Publication date
US20170360793A1 (en) 2017-12-21
ES2761776T3 (es) 2020-05-21
JP6716570B2 (ja) 2020-07-01
JP2018500364A (ja) 2018-01-11
JP6916933B2 (ja) 2021-08-11
EP3659605A1 (en) 2020-06-03
EP3236967A1 (en) 2017-11-01
CN112675178A (zh) 2021-04-20
AU2015370666B2 (en) 2020-09-03
EP3236967B1 (en) 2019-10-16
CN107206000A (zh) 2017-09-26
JP2020147593A (ja) 2020-09-17
AU2015370666A1 (en) 2017-08-10
DK3236967T3 (da) 2020-01-02
US11324746B2 (en) 2022-05-10
WO2016102952A1 (en) 2016-06-30
PT3236967T (pt) 2020-01-06

Similar Documents

Publication Publication Date Title
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
IL254435A0 (en) Optimal combined therapy and its use for the treatment of cancer and autoimmune disease
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
IL276733A (en) Use of Aribolin in cancer treatment
SG11201701035SA (en) Cancer diagnosis and therapy
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
IL290251A (en) Combination for effective treatment of metastatic cancer in patients
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
EP3151821A4 (en) Marmelin analogs and methods of use in cancer treatment
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
PL3236967T3 (pl) Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego
PL3212280T3 (pl) Dopasowanie szumu usznego u pacjentów z implantem ślimakowym (CI) i implantem słuchowym pnia mózgu (ABI)
IL251825B1 (en) Treatment of cancer and skin damage
IL245998B (en) Pharmaceutical preparations for the treatment of metastatic cancer and its prevention
GB201611245D0 (en) Prevention and treatment of metastatic disease in thrombosytotic cancer patients
GB201612793D0 (en) Therapeutic use of quesnoin in colorectal cancer treatment
GB201609690D0 (en) Therapeutic use of norfluxetine in breast cancer treatment
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer
GB201317373D0 (en) Treatment and prevention of cancer
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
GB201301685D0 (en) Diagnosis and treatment of cancer